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Abstract: Atrial Fibrillation (AF) may be diagnosed due to symptoms, or it may be found as an
incidental electrocardiogram (ECG) finding, or by implanted devices recordings in asymptomatic
patients. While anticoagulation, according to individual risk profile, has proven definitely beneficial
in terms of prognosis, rhythm control strategies only demonstrated consistent benefits in terms of
quality of life. In fact, evidence collected by observational data showed significant benefits in terms
of mortality, stroke incidence, and prevention of cognitive impairment for patients referred to AF
catheter ablation compared to those medically treated, however randomized trials failed to confirm
such results. The aims of this review are to summarize current evidence regarding the treatment
specifically of subclinical and asymptomatic AF, to discuss potential benefits of rhythm control
therapy, and to highlight unclear areas.
Keywords: subclinical atrial fibrillation; stroke; ischemic cerebral events; catheter ablation; screening;
cognitive impairment
1. Introduction
Atrial fibrillation (AF), the most common sustained arrhythmia [1], is associated with an increased
risk of thromboembolic events such as transient ischemic attack (TIA), ischemic stroke with overt
neurological sequelae [2], or micro-embolic events resulting in subclinical brain lesions (revealed by
neuroimaging techniques). On the other hand, AF is independently associated with a higher risk
of developing dementia [3], with up to a 30% increased risk regardless of clinical cerebrovascular
events [4]. Therefore, given the high prevalence of AF in the general population and its considerable
impact on both life expectancy and quality of life, correct and prompt management of the arrhythmia
is mandatory. However, early diagnosis can be difficult in the case of an asymptomatic presentation,
defined as sustained AF episodes in patients not presenting palpitations, dyspnea, fatigue, or other AF
related symptoms [5]. The exact percentage of asymptomatic presentations among patients with AF
has not been clearly established. Different studies provide estimates between 10% and 40%, according
to the characteristics of the population in exam [6–10]. A higher prevalence has been reported in
patients with persistent AF, males, elderlies, and in the presence of relevant comorbidities [7]. However,
subclinical AF can also be diagnosed in patients with fewer risk factors [10] as paroxysmal AF, for
example, at the early phase of arrhythmia development and progression. Moreover, variability in
terminology among studies, as later discussed, increases uncertainty related to the description of
asymptomatic AF.
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In the present review, we shed light on several aspects of this clinical entity, highlighting doubtful
elements for which further research is needed: first, we discuss the complex pathophysiological links
between AF, dementia, and stroke, focusing on the clinical impact of asymptomatic AF, which has
been demonstrated not to be a benign condition. Subsequently, we address the issue of screening
for AF, which is of great interest from both a clinical and population medicine point of view. Finally,
we discuss management of the patient with asymptomatic and subclinical AF, considering clinical
recommendations, anticoagulation, antiarrhythmic drugs (AAD) therapy, and catheter ablation.
2. Definitions
Despite being a widely discussed topic, terminology in literature is often inconsistent and the
terms “asymptomatic AF”, “subclinical AF”, “silent AF”, and “atrial high rate episodes (AHRE)”
are used to identify different entities (Table 1). Different studies define “asymptomatic AF” as AF
diagnosed incidentally [11] or by ECG in patients reporting no symptoms, or, alternatively, with
European Heart Rhythm Association (EHRA) score 1 [6–10,12]. Other studies [6,7,10] consider silent
AF and asymptomatic AF as synonyms. The STROKESTOP trial names AF “silent AF” when the
diagnosis is established through screening [13]. However, in other experiences [14–16] assessing the
benefit of AF screening, the arrhythmia diagnosed through a screening program is simply referred to
as AF. Conversely, AHRE are defined, with variable temporal cutoffs according to different studies, as
atrial tachycardia episodes recorded by the intra-atrial electrode of implanted devices. However, when
an intra-atrial electrogram is available, as in the subgroup of patients of the ARTESiA trial [17], the
arrhythmia episode has been defined as “subclinical AF” and not as AHRE. Instead, the ASSERT trial
refers to AHRE as subclinical AF [18]: in this study the devices were able to detect atrial arrhythmias,
but it remains unclear whether the electrograms were finally analyzed to define the episodes or not.
These studies, in fact, consider both asymptomatic and symptomatic AF as “clinical” only when
diagnosed by surface ECG. For the purpose of this review we consider device detected atrial tachycardia
without electrogram documentation as AHRE; subclinical AF refers to AF either diagnosed through
screening programs, incidental findings during routine ECG, or after implanted device electrograms
analysis; finally, we define asymptomatic AF in patients with a clearly established AF diagnosis,
undergoing a defined clinical management and who remain asymptomatic based on physician’s
evaluation. According to these definitions, subclinical and asymptomatic AF are a continuum in the
diagnostic process and subsequent management of AF: in fact, once the diagnosis has been confirmed
and treatment has begun, subclinical AF should be referred to as clinical asymptomatic AF.
Table 1. Details on the terminology used in available literature.
Authors
(Study Year)
AHRE/Subclinical/Asymptomatic AF
Diagnostic Method
Terminology Used in the
Study
Terminology Used
in This Review
Implanted device monitoring
Glotzer et al.
(2003) [19]
AHRE: atrial rate ≥ 220 bpm lasting at least
5 min (detected by pacemaker) AHRE
AHREGlotzer et al.
(2006) [20] AHRE: atrial rate > 175 bpm lasting at least 20 s
Device-detected atrial
tachycardia (AT)/AF burden
(AHRE)
Hohnloser et al.
(2006) [21]
AHRE: atrial rate ≥ 190 bpm lasting at least
6 min (detected by pacemaker or ICD) Asymptomatic AF/AHRE
Ip et al. (2009)
[22]
AHRE: atrial rate ≥ 220 beat/min lasting at least
5 min, AHRE
Kirchhof et al.
(2017) [23]
AHRE: atrial rate ≥ 180 bpm lasting at least
6 min AHRE
Lopes et al.
(2017) [17]
One episode of device-detected subclinical AF
lasting at least 6 min. Subclinical AF requires at
least one episode of electrogram confirmation
Subclinical AF Subclinical AF
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Table 1. Cont.
Authors
(Study Year)
AHRE/Subclinical/Asymptomatic AF
Diagnostic Method
Terminology Used in the
Study
Terminology Used
in This Review
Non-Invasive ECG monitoring
Flaker et al.
(2005) [12]
AF diagnosed with ECG or rhythm strip.
Symptoms evaluated by a questionnaire Asymptomatic AF
Asymptomatic AFRienstra et al.
(2014) [10]
Recurrent persistent AF without symptoms
according to a questionnaire Asymptomatic AF/Silent AF
Boriani et al.
(2015) [7] ECG diagnosed AF and EHRA score I Asymptomatic AF/Silent AF
Freeman et al.
(2015) [9]
Electrocardiographically documented AF and
EHRA score I Asymptomatic AF
Bakhai et al.
(2016) [6] ECG diagnosed AF and EHRA score I Asymptomatic AF/Silent AF
Siontis et al.
(2016) [11]
AF detected incidentally (routine physical
examination, preoperative evaluation,
emergency department or clinic visit for
unrelated problem)
Asymptomatic AF
Subclinical AF
Jaakkola et al.
(2017) [15] ECG diagnosis in a screening program AF
Halcox et al.
(2017) [16] Device detected AF in a screening program AF
Friberg et al.
(2013) [13]
Device detected AF in a screening program and
confirmed by Holter for uncertain cases Silent AF
AF: atrial fibrillation; AHRE: atrial high rate episodes; ICD: implantable cardioverter-defibrillator.
3. Pathophysiological Links between AF, Dementia, and Stroke
AF confers an increased risk of cognitive decline and dementia development independently from
stroke occurrence. Indeed, this has been recently demonstrated in a large cohort study conducted
on 262,611 patients registered in the Korea National Health Insurance Service—Senior, 60 years of
age or older and no history of valvular heart disease, stroke, dementia, and AF before enrolment [24].
After adjustment, in the incident AF population the risk of developing dementia was increased after
censoring for stroke (HR, 1.27; 95% CI 1.18–1.37). Interestingly, anticoagulation therapy was associated
with a lower risk of developing dementia (HR, 0.61; 95% 0.54–0.68). These results are consistent, in
fact, with a recent meta-analysis showing a 30% increased risk of AF patients to develop dementia
regardless of cerebrovascular events [4].
The association between AF and cognitive impairment in patients without clinical stroke has
been linked to several possible mechanisms: micro-embolic events occurring in cerebral circulation
may lead to silent cerebral ischemia (SCI), visible by neuroimaging techniques as magnetic resonance
imaging (MRI). The correlation between SCIs and cognitive impairment has been demonstrated by
ad hoc questionnaires and tests designed to examine cognitive function, both in retrospective [25]
and prospective studies [26]. Additionally, a computational analysis showed that AF directly affects
cerebral hemodynamic, resulting in hypoperfusions and hypertensive events, possibly associated with
non-embolic SCI and microbleedings in the deep cerebral circle [27,28]. Dementia and cognitive decline,
however, can also be caused by clinical strokes, a well-known and feared complication of AF. Several
questions on the relation between AF and stroke are actually still unsolved: the classical mechanism,
based on the Virchow’s triad [29], by which AF causes strokes is thrombus formation in the left atrium
(typically in the left atrial appendage), and its subsequent embolism in a cerebral vessel. Nevertheless,
studies conducted in patients with implanted devices and who suffered a thromboembolic event
showed that, in a large portion of patients, no AF events occurred the months before [30,31].
The link between fibrosis and AF is rather complex, since AF causes atrial remodeling and fibrosis
itself causes and sustains AF. Animal experimental models demonstrated that sustained AF induces
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several structural changes in atrial myocytes, including glycogen accumulation, sarcomeres reduction,
mitochondrial modification, collagen deposition, and fibrosis [32]. Late gadolinium enhancement MRI
studies demonstrated that more severe atrial remodeling with extensive fibrosis is associated with more
advanced disease and a higher risk of AF recurrences after catheter ablation [33]. Voltage map during
invasive procedures demonstrated that the magnitude of atrial fibrosis is greater in persistent [34] in
comparison to paroxysmal AF, and it predicts ablation success [35]. Finally, AF can be a marker of other
atrial abnormalities including atrial dilation, left atrial appendage dysfunction, endothelial disease;
all these features may cause thromboembolic stroke without an AF episode occurring prior to the
cerebrovascular event. Indeed, an “atrial cardiomyopathy” exists, according to which extensive atrial
disease can be, at least partially, the cause rather than the consequence of AF [36,37]. Therefore, it has
been proposed [30] that AF can cause atrial remodeling and be the manifestation of an atrial disease
that increases per se the risk of stroke and thrombi formation, independently from the heart’s rhythm.
Actually, the association between dementia and the different clinical presentation of AF has not
been thoroughly analyzed. In fact, no published studies directly analyzed cognitive impairment in
patients with asymptomatic AF. Several studies evaluated the relation between subclinical AF and the
risk of stroke, focusing on subclinical atrial tachyarrhythmia detected by implanted devices. Indeed, it
has been thoroughly demonstrated that evaluation of pacemakers recordings is a reliable method to
detect AF [38]. The TRENDS trial [39], in fact, evaluated stroke and systemic thromboembolic events in
patients with at least one stroke risk factor (defined by the CHADS2 score) by assessing pacemaker or
defibrillator recordings. The study was meant to detect a difference in stroke rate among patients with
a high, low burden, or no events of atrial arrhythmias/tachycardia (AHRE). Unfortunately, the study
failed to show any significant differences, likely due to underpowering as the event rate was lower than
expected. An ancillary analysis of the MOST study, instead, demonstrated that AHRE in patients with
sinus node dysfunction conferred an increased risk of stroke, death, and to develop clinical AF [19].
Of note, patients with previously diagnosed supraventricular arrhythmia were not excluded, and a
large portion of patients with AHRE presented symptoms. Nevertheless, the authors concluded that
symptoms were poorly correlated with and were not reliable markers of AHRE. Analogous results
were found in the ASSERT trial, which demonstrated that AHRE in patients without a history of AF
confer a greater risk of developing clinical AF and are associated with a higher rate of stroke and
systemic thromboembolic events [18].
Finally, also AF burden needs consideration: as thoroughly explained by Kennedy [40], AF burden
defines the overall amount of AF duration among each patient, providing additional insight on
the magnitude of AF episodes. Many clinical conditions (such as, genetics, obesity, hypertension,
diabetes, heart failure, older age [40]) affect AF burden and have an important role in AF morbidity.
Indeed, it is now clear that prompt correction of comorbidities and cardiovascular risk factors reduces
AF burden [41,42] and is, therefore, recommended in all patients suffering from AF [43,44]. Several
arrhythmic entities, including AHRE, detected by non-invasive ECG monitoring and implanted devices,
are markers of AF and contribute to define the AF burden [40]: however, despite the association
between persistent AF and worse prognosis [45–47], current guidelines suggest to base the decision of
anticoagulation therapy for stroke prevention on patient’s risk factors (quantified by CHA2DS2-VASc
score) and not on AF burden. In fact, an AF burden cutoff identifying an increased risk of stroke or
mortality has not yet been established, and its quest is at the heart of many studies.
4. Asymptomatic AF and Its Impact on Prognosis
Whether asymptomatic presentation of AF confers a worse prognosis than symptomatic AF
is still debated (Table 2). A prospective observational study conducted by Boriani et al. on 3119
patients with AF (the EORP-AF Registry) demonstrated that patients with asymptomatic AF, in
comparison to symptomatic patients, have a worse prognosis and an increased risk of mortality at
1 year. At multivariate analysis, however, EHRA score I was not independently associated with
a worse prognosis. Therefore, increased mortality was likely mainly driven by the differences in
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patients’ comorbidities and global risk rather than to the different AF presentation [7]. Another study
reported that both patients with subclinical AF and atypical presentations of AF (fatigue, shortness of
breath, chest pain, light-headedness, syncope, decreased exercise tolerance without palpitations) are at
higher risk of cerebrovascular events (CVE) in comparison with patients with typical AF symptoms
(palpitations). Moreover, the risk of cardiovascular and global mortality was greater in asymptomatic
patients after adjustment for confounding factors (CHA2DS2-VASc score and age) [11]. A sub-study
conducted on the PREFER in AF Registry showed that ischemic stroke and TIA occurred with similar
frequency in symptomatic and asymptomatic patients [6]. These results confirm, in fact, those of a
retrospective analysis of the AFFIRM trial that revealed no differences in outcomes after adjustment
for baseline characteristics between patients with asymptomatic and symptomatic AF [12]. Conversely,
in a sub-analysis of the RACE study, asymptomatic AF was associated with improved prognosis
(lower hospitalization due to heart failure and antiarrhythmic drugs adverse effect rate) in comparison
with symptomatic patients, but no differences were found on the risk of thromboembolic events [10].
However, these trials were not designed to evaluate the prognostic implications of different subtypes
of AF, and AF presentation was not considered when deciding treatment throughout follow up.
Table 2. Summary of studies on the clinical relevance of asymptomatic and subclinical atrial
fibrillation (AF).
Authors
(Study Year)
AHRE/Subclinical/Asymptomatic
AF Diagnostic Method
Stroke and TE Incidence
(%) * Mortality (%) *
Correlation with
Stroke or
Mortality
Implanted device monitoring
Glotzer et al.
(2003) [19]
AHRE: atrial rate ≥ 220 bpm
lasting at least 5 min (detected by
pacemaker)
AHRE: 33/160 (20.6) No
AHRE: 16/152 (10.5)
AHRE: 28/160 (17.5)
No AHRE: 16/152
(10.5)
Yes (for total
mortality, stroke,
and AF
development)
Glotzer et al.
(2009) [39]
AHRE: atrial rate > 175 bpm
lasting at least 20 s. Patients were
stratified according to 30 days
window monitoring in: zero, low,
and high AHRE burden
Annualized TE incidence
rate: zero AHRE burden
1.1%; Low AHRE burden
1.1%; High AHRE burden
2.4%
NA No
Healey et al.
(2012) [18]
AHRE: atrial rate ≥ 190 bpm
lasting at least 6 min (detected by
pacemaker or ICD)
AHRE in the previous 3
months: 11/261 (4.2) No
AHRE in the previous 3
months: 40/2319 (1.7)
From vascular causes
AHRE in the previous
3 months: 19/261 (7.3)
No AHRE in the
previous 3 months:
153/2319 (6.6)
Yes
Non-Invasive ECG monitoring
Flaker et al.
(2005) [12]
AF diagnosed with ECG or rhythm
strip. Symptoms evaluated by a
questionnaire
Asymptomatic AF: 21
Symptomatic AF: 136
Asymptomatic AF: 60
(19) Symptomatic AF:
606 (27)
No (in comparison
with symptomatic
patients)
Rienstra et al.
(2014) [10]
Recurrent persistent AF without
symptoms according to a
questionnaire
Asymptomatic AF: 8/157
Symptomatic AF: 28/365
Asymptomatic AF:
9/157 Symptomatic AF:
26/365 (death from
cardiovascular causes)
No †
Boriani et al.
(2015) [7]
ECG diagnosed AF and EHRA
score I
EHRA I: 10/962 (1.0%)
EHRA II–IV: 15/1344
(1.1%)
EHRA I: 102/1086
(9.4%) EHRA II–IV:
65/1556 (4.2%)
Yes (for mortality
compared to
symptomatic
patients)
Freeman et
al. (2015) [9]
Electrocardiographically
documented AF and EHRA score I
EHRA I: 99/3682 EHRA
II–IV: 168/5918
EHRA I: 311/3682
EHRA II–IV: 561/5918 No ‡
Bakhai et al.
(2016) [6]
ECG diagnosed AF and EHRA
score I
EHRA I: ischemic stroke
8/489 (1.6) TIA 7/488 (1.4)
arterial embolism 2/488
(0.4) EHRA II–IV: ischemic
stroke 44/5514 (0.8) TIA
73/5510 (1.3) arterial
embolism 11/5514 (0.2)
NA
No (only EHRA
score IV was
associated with a
higher events
occurrence)
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Table 2. Cont.
Authors
(Study Year)
AHRE/Subclinical/Asymptomatic
AF Diagnostic Method
Stroke and TE Incidence
(%) * Mortality (%) *
Correlation with
Stroke or
Mortality
Siontis et al.
(2016) [11]
AF detected incidentally (routine
physical examination, preoperative
evaluation, emergency department,
or clinic visit for unrelated
problem)
HR compared to typical
AF: Subclinical AF 2.60
(95% C.I. 1.10–6.11)
Atypical AF 3.12 (95% C.I.
1.27–7.66)
HR compared to
typical AF: Subclinical
AF 4.01 (95% C.I.
2.32–6.91) Atypical AF
3.19 (95% C.I.
1.78–5.71)
Yes (compared to
typical AF)
AF: atrial fibrillation; AHRE: atrial high rate episodes; NA: not applicable; TIA: transient ischemic attack; TE:
thromboembolism * If not otherwise indicated. † In this study asymptomatic AF compared to symptomatic
presentation conferred a lower risk of heart failure and severe antiarrhythmic drugs adverse effects. ‡ In this study
AF symptoms and decreased quality of life were associated with higher risk of hospitalization.
Bearing in mind that the first manifestation of AF can be an ischemic stroke with severe
consequences (as death, dementia, and lower quality of life), that AF is first diagnosed in 11%–24% of
patients with recent ischemic stroke or TIA [48,49], and that AF-associated strokes have a high risk of
recurrences, interest in the screening for subclinical AF has grown during the recent years.
5. Screening for Atrial Fibrillation
A screening program to early detect subclinical AF entails several questions: what is the appropriate
method for the screening? Who should be screened? Is a screening program cost-effective? Current
European guidelines for the management of AF suggest opportunistic screening in patients older than
65 years by pulse check or single-lead ECG portable devices (Class of recommendation I). In patients
with an implanted device it is recommended to evaluate the occurrence of AHRE on a regular basis:
if AHRE are detected, AF must be searched by further electrocardiographic monitoring prior to
starting treatment. In patients with cryptogenic ischemic stroke or TIA an initial ECG followed by
electrocardiographic monitoring for 72 h is recommended (Class of recommendation I), and a long
term strategy should be considered (Class of recommendation IIa) [5]. The AHA/ACC/HRS guidelines,
instead, do not provide definite recommendations for screening [50]. In addition, a statement
appears suggesting that ECG based screening does not improve detection rate of asymptomatic AF in
comparison with a pulse palpation based approach, and there are currently no evidence to support the
benefits of an ECG based screening [51,52].
Several methods have been proposed for AF screening in populations with risk factors: pulse
palpation has been described as an effective method to detect subclinical AF [14]. However,
pulse characteristics are seldom evaluated in primary care settings and adequately trained patients’
compliance in self-monitoring is low in the long term [15]. Handheld ECG is a reliable and effective
method for AF screening in at risk populations, with a fourfold increase in AF diagnosis over 12 months
according to the REHEARSE-AF study [16]. This study showed that stroke and TIA incidence was not
statistically different in screened and unscreened patients. However, clinical events were not considered
as a primary outcome, and the study was not designed and powered to detect a significant difference in
these events. The ongoing STROKESTOP trial aims at evaluating the efficacy and cost effectiveness in
reducing stroke incidence of an AF screening program based on single lead discontinuous ambulatory
ECG monitoring in a 75–76 years old population from two regions in Sweden [13]. An analysis of
the ongoing investigation demonstrated that this strategy increased AF detection fourfold, as AF has
been first diagnosed in 3% of the screened-population; 93% of patients with new detection of AF have
initiated oral anticoagulation (OAC) therapy [53]. Awaiting for the conclusion of the trial and its
final results, a simulation study based on the study design and available data of this trial, concluded
that screening for AF with an ECG recorder is cost effective with a reduction of eight strokes, and an
increase of 11 life-years and 12 quality-adjusted life years (QALYs) per 1000 screened patients [54].
In patients who suffered a cryptogenic stroke and in whom standard 24 h ECG monitoring failed
to detect AF, two randomized trials, instead, demonstrated the benefits of further prolonging rhythm
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monitoring. The CRYSTAL-AF trial [55,56] randomized 441 patients, 40 years of age or older, who
suffered a cryptogenic stroke or TIA, without history of AF and no other indications to anticoagulant
therapy, to implant a cardiac monitoring device or standard care: the AF detection rate was higher in
the long term monitoring strategy group both at 6 and 12 months (HR 6.4; 95% CI 1.9–21.7; HR 7.3; 95%
CI 2.6–20.8, respectively). The EMBRACE trial [57] compared standard care and 30-days non-invasive
ECG monitoring to detect AF in patients over 55 years old, with cryptogenic stroke or TIA within the 6
months prior to randomization. By 90 days after the randomization AF lasting 30 s was detected in
significantly more patients in the intervention group (absolute difference 12.9%, 95% CI 8.0–17.6), with
a number needed to screen of eight. Moreover, in the AHA/ACC/HRS focused update of AF guidelines
recommendation for the use of implantable device for AF detection after cryptogenic stroke has been
implemented, according to which a more extensive and thorough long-term cardiac monitoring needs
to be considered [44].
6. Management of Subclinical and Asymptomatic AF
6.1. Clinical Approach to the Patient with Asymptomatic Atrial Fibrillation
Clinical approach to a patient with asymptomatic AF is indeed complex and needs to take into
account several aspects of the arrhythmia and presence of comorbidities. First, it must be taken into
consideration that asymptomatic AF patients are not always truly asymptomatic, since they may
undergo progressive involuntary lifestyle restriction or suffer unrecognized anxiety or depression;
moreover, a large portion of AF patients may already present cerebral ischemic lesions (about four
out of 10 according to results of the prospective observational SWISS-AF study [58]) which have
been demonstrated to affect cognitive functions [26,58]. To assess definitively whether a patient is
truly asymptomatic, cardioversion should be performed, and symptoms and quality of life evaluated
after sinus rhythm restoration; subsequently, in those who felt improvement after sinus rhythm
restoration, a rhythm control strategy should be pursued. It has been demonstrated that catheter
ablation for AF significantly improves quality of life and symptoms [59,60]: however subanalysis of
these studies demonstrated that, once the patients were divided according to symptoms intensity, the
observed benefit was mostly driven by patients with more severe symptoms, whereas those who at
baseline were barely symptomatic had little or no improvement after ablation. Therefore, patients’
symptoms (not only typical AF symptoms such as palpitations, but also fatigue and dyspnea) and
exercise tolerance should be thoroughly examined and a quality of life questionnaire administered;
comorbidities should be evaluated, since they can be a cause of symptoms experienced by the patient,
and promptly treated. Control of cardiovascular risk factors, hypertension, smoke habit, sedentary
life, and obesity should be also encouraged and recommended, as they worsen symptoms and play a
role in disease progression [44]. Finally, a regular cardiological follow-up is recommended, including
clinical examination for heart failure signs and echocardiographic control of ejection fraction; the latter,
in fact, is a crucial aspect to promptly recognize and address patients with a reduced ejection fraction
to rhythm control strategy by catheter ablation in order to prevent further heart failure progression [5]
and reduce mortality, as suggested by the recent CASTLE-AF findings [61].
Treatment strategies for prevention of cognitive decline are, instead, debated [62]: in addition
to physical exercise and optimal control of cardiovascular risk factors, appropriate anticoagulation
therapy is recommended; non-vitamin K antagonist oral anticoagulants (NOAC) should be preferred
because of the higher safety profile. Moreover, a rhythm control strategy, including catheter ablation,
is indicated; nevertheless, it should be borne in mind that the benefit of restoring sinus rhythm may be
partially offset by subclinical cerebral lesions occurring during the procedure [63,64].
6.2. Anticoagulation Therapy
The cornerstone of AF therapy for prevention of stroke and systemic thromboembolic events
is OAC therapy. The 2016 ESC guidelines recommend to initiate OAC therapy upon evaluation of
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the individual stroke risk based on the number of CHA2DS2-VASc risk factors; in the absence of
contraindications, OAC therapy is recommended when the CHA2DS2-VASc score is≥2 in male patients
or ≥3 in female patients and it should be considered with CHA2DS2-VASc scores 1 or 2 respectively.
Whereas vitamin K antagonists are the only recommended anticoagulants for valvular AF patients, i.e.,
patients with mechanical heart valve or moderate to severe mitral stenosis, NOAC should be preferred
in non-valvular AF patients [5]. The net benefit of CHA2DS2-VASc-guided OAC therapy in preventing
stroke occurrence and recurrence in AF patients has been thoroughly demonstrated [65,66]. A large
meta-analysis showed the superiority of NOAC over VKA with respect to safety and efficacy [67].
As far as OAC therapy in subclinical AF or AHRE is concerned, there is actually no direct
evidence that early initiation of OAC treatment in this setting can improve hard clinical endpoints
without significantly increasing bleeding risk [51]. It has been proposed that intermittent OAC might
provide a better balance between stroke prevention and bleeding risk than uninterrupted OAC therapy.
Nevertheless, the IMPACT trial, which evaluated intermittent versus OAC initiated upon standard
physician’s indication after detection of AHRE at implanted defibrillator follow-up sessions, failed to
show clinical benefit regarding the composite outcome of stroke, systemic embolism, and bleeding
events (HR 1.06; 95% CI 0.75–1.51; p value: 0.732) [68]. In this perspective, two ongoing clinical trials are
designed to assess the feasibility of continuous OAC therapy in patients with subclinical AF or AHRE
recorded by implanted devices (Table 3). The randomized, double-blind, multicenter NOAH-AFNET
6 study, including older patients (>65 years old) with at least one additional CHA2DS2-VASc risk
factor but without clinical AF nor any other indication to OAC therapy, will evaluate the efficacy of
edoxaban compared to aspirin or no antithrombotic therapy in preventing stroke, cardiovascular death,
and systemic embolism after AHRE detection by implanted devices’ recordings; the primary safety
endpoint will be major bleeding [23]. The ARTESiA trial is a prospective, multicenter, double-blind,
randomized controlled trial, which enrolls patients with risk factors for stroke and subclinical AF
detected by implanted devices; patients will be randomized to either apixaban or aspirin with a
primary composite endpoint of stroke, TIA, and systemic thromboembolic events during an estimated
follow-up of 3 years [17].
Table 3. Details of ongoing trials.
Name of Study Number of Patients Study Arms Primary Endpoints Secondary Endpoints
STROKESTOP
(NCT01593553)
7173 (in screening)
14,381 (controls not
screened)
Intervention
group: ECG
screening for AF
using intermittent
ECG recorder.
Control group:
standard of care
Composite of ischemic
and hemorrhagic
stroke, systemic
embolism, major
bleeding requiring
hospitalization, and
all-cause mortality
Each single component of the
composite primary outcome;
dementia; cardiovascular
mortality; hospitalization due to
cardiovascular disease;
cost-effectiveness; OAC
initiation and compliance; AF
detection; pulmonary embolism
and deep vein thrombosis
NOAH-AFNET 6
(NCT02618577)
2686 (3400 estimated)
patients (≥65 years
old and ≥1 additional
CHA2DS2-VASc
factor) with AHRE
documented by
implanted devices
Intervention
group: Edoxaban
(standard AF
dosing) Control
group: ASA or
placebo
Composite of stroke,
systemic embolism and
cardiovascular death
(measured as time
from randomization to
event occurrence)
MACE (cardiac death, MI, acute
coronary syndrome), all-cause
death, major bleeding events,
quality of life changes at 12 and
24 months, patient satisfaction
at 12 and 24 months, cost
effectiveness and health
resource utilization, autonomy
status changes in patients
affected by stroke during study
participation, cognitive function
at 12 and 24 months
ARTESiA
(NCT01938248)
≈4000 patients with
subclinical AF at high
risk for stroke
(estimated)
Intervention
group: Apixaban
(standard AF
dosing) Control
group: ASA (81
mg/die)
Efficacy outcome:
composite of stroke
(including TIA) and
systemic embolism.
Safety outcome: major
bleeding
Ischemic stroke; MI; vascular
death; total death; composite of
stroke, MI, systemic embolism
and total death; composite of
stroke, MI, systemic embolism,
total death, and major bleeding.
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Table 3. Cont.
Name of Study Number of Patients Study Arms Primary Endpoints Secondary Endpoints
EAST
(NCT01288352)
2789 patients with
new AF (<1 year) and
risk factors for stroke
Intervention
group:
guidelines-based
therapy andearly
rhythm control
therapy (AAD or
PVI) Control
group: usual care
First coprimary
outcome: composite of
cardiovascular death,
stroke (including TIA),
acute coronary
syndrome, and
worsening of heart
failure. Second
coprimary outcome:
nights in hospital per
year
Cardiovascular death, stroke,
worsening of heart failure, acute
coronary syndrome, time to
recurrent AF, cardiovascular
hospitalizations, all-cause
hospitalizations, left ventricular
function, quality of life,
cognitive function
OCEAN
(NCT02168829)
1572 patients free
from AF for at least 1
year after catheter
ablation for
non-valvular AF
(estimated)
Active
Comparator:
rivaroxaban 15
mg/die Active
Comparator: ASA
75–160 mg/die
Composite of clinically
overt stroke, systemic
embolism, and covert
stroke detected by
brain MRI
Each single component of the
composite primary outcome;
major bleeding, clinically
relevant non-major bleeding,
minor bleeding and their
composite; overt intracranial
hemorrhage; microbleedings as
detected by MRI; TIA; all-cause
mortality; net clinical benefit;
occurrence of nonprimary end
point MRI changes; correlation
of AF burden/recurrence to
occurrence of clinical or covert
stroke; neuropsychological
testing; quality of life
OAT
(NCT01959425)
100 patients free from
AF for at least 3
months after catheter
ablation and at high
risk for stroke
(estimated)
Intervention
group: OAC
discontinuation
Control group:
OAC continuation
Composite of any
major thromboembolic
event and major
hemorrhagic
complication
Bleeding; hospitalization;
mortality; quality of Life; AF
recurrence; repeat ablation
SWISS-AF
(NCT02105844) 2415 AF patients NA
Stroke or systemic
embolism Hospitalization for heart failure
AAD: antiarrhythmic drugs; AF: atrial fibrillation; AHRE: atrial high rate episodes; ASA: acetylsalicylic acid;
MACE: major adverse cardiovascular events; MI: myocardial infarction; MRI: magnetic resonance imaging; NA: not
applicable; OAC: oral anticoagulant; PVI: pulmonary veins isolation; TIA: transient ischemic attack.
6.3. Anti-Arrhythmic Drug Management
A rhythm control approach in the subset of patients with subclinical and asymptomatic AF is
perhaps even more controversial than the previously discussed OAC therapy. The AFFIRM [69,70] and
RACE [71] trials demonstrated no advantage on mortality and stroke in pursuing a rhythm control
over a rate control strategy in AF patients. Nevertheless, the CASTLE-AF [61] study showed a clear
benefit in cardiovascular death and hospitalizations for worsening heart failure in patients with heart
failure and paroxysmal or persistent AF treated by catheter ablation. According to current European
guidelines, rhythm control therapy is recommended in symptomatic patients presenting with recent
onset AF in order to improve quality of life [5].
Some considerations are needed in this regard. First, a subanalysis of the AFFIRM [72] study
showed that maintaining sinus rhythm confers half the risk of death compared to AF persistence.
AAD, however, were associated with increased mortality after adjustment for sinus rhythm restoration,
therefore the authors concluded that the beneficial effects of AAD in maintaining sinus rhythm were
offset by their adverse effects, resulting in no net survival advantage. Similarly, an observational
study [73] comparing stroke and TIA incidence in patients treated with either rate or rhythm control
strategy (n = 41.193 and 16.325 respectively) showed that rhythm control strategy was associated with
a lower risk of stroke and TIA during a mean follow-up of 2.8 years at multivariate analysis (HR 0.80;
95% CI 0.74–0.87). After stratification for CHADS2 score, absolute stroke and TIA incidences were
reduced only in patients with CHADS2 score ≥ 2.
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6.4. Catheter Ablation
The aforementioned studies compared only AAD with rate control therapy, but AF catheter
ablation has now become an effective and widespread option for rhythm control: indeed, ESC
guidelines do recommend catheter ablation as a first-line alternative to AAD in symptomatic patients
with paroxysmal AF. A large meta-analysis [74] including 1481 patients with AF and 11 randomized
controlled trials compared the efficacy and safety of catheter ablation versus AAD therapy (n = 785
and 696 respectively): catheter ablation was associated with lower AF recurrences (RR, 0.40; 95% CI
0.31−0.52; p value = 0.00001) both as first- and second-line approaches (RR, 0.52; 95% CI, 0.30−0.91;
p value = 0.02 and RR, 0.37; 95% CI, 0.29−0.48; p value < 0.00001, respectively), but there was a
significant increase of adverse events incidence (RR, 2.04; 95% CI, 1.10–3.77; p value = 0.02). However,
after stratification by date, no difference in safety endpoints was found considering only the results of
the studies conducted after 2009 (RR, 1.51; 95% CI, 0.55–4,15; p value = 0.42). This finding may be due
to increased experience and improved technology in catheter ablation, leading to lower complications
and adverse events.
Since catheter ablation proved more effective than AAD therapy in maintaining sinus rhythm [74],
it has been hypothesized that indication to this procedure could reflect into better long-term prognosis.
However, the recent CABANA trial [75], which was supposed to shed light on this clinical dilemma,
failed to demonstrate a statistically significant superiority of catheter ablation over both rhythm and
rate control pharmacological therapy for a composite primary endpoint including death, disabling
stroke, serious bleeding, or cardiac arrest (HR, 0.86; 95% CI 0.65–1.15; p value = 0.30). A detailed
analysis of the results, however, shows that the study was characterized by a greater than expected
cross-over between treatment groups, with 301 (27.5%) patients assigned to medical therapy switching
to catheter ablation. Indeed, in the 12-month per-protocol analysis of the results, patients who had
undergone catheter ablation presented a reduced risk of meeting the primary endpoint than those
managed pharmacologically (HR 0.73; 95% CI 0.54–0.99).
Several other investigations, albeit limited by their unrandomized nature, provided evidence in
favor of catheter ablation. One study comparing patients with similar CHADS2 scores showed that
catheter ablation confers a risk of ischemic stroke similar to that of the population without AF, but
the details on OAC treatment were lacking [76]. A multicenter study conducted by Hunter et al. [77]
compared patients undergoing AF ablation with a cohort treated with medical therapy and an AF-free
cohort representing the general population; of note, in the medical therapy cohort CHADS2 score was
higher than in catheter ablation group (1.6 ± 1.2 and 0.7 ± 0.9 respectively). After a mean follow-up
of 3.1 years, catheter ablation was associated with a lower risk of stroke and death in comparison
with medical therapy, presenting a stroke rate comparable to the general population. Moreover,
freedom from AF was a protective factor against stroke at multivariate analysis (HR 0.33; 95% CI
0.17–0.67). Discontinuation of OAC therapy occurred in 64% of patients who underwent pulmonary
veins (isolation (85% of these were on single antiplatelet agent therapy) and it was more frequent
in patients without AF recurrences in comparison to patients with AF recurrences, despite a small
difference in CHADS2 score between the two groups (0.7 ± 0.9 vs. 0.9 ± 0.9, respectively). These
findings confirm those of another observational study [78] which reported no statistically significant
difference between patients who stopped or continued OAC after AF ablation. Along with history
of stroke, and unlike OAC interruption, except in intermediate risk patients, recurrent AF was a
predictor of thromboembolic events, whereas OAC continuation was associated with an increased
risk of bleeding. Another multicenter observational study [79] recruiting 1500 AF patients compared
rate control and OAC therapy with catheter ablation associated with either OAC continuation or
discontinuation after the procedure: no differences were found as for thromboembolic events incidence
(2.2% in rate control strategy and OAC, 1% in catheter ablation with OAC, 1.4% catheter ablation and
OAC discontinuation, p value = 0.45), whereas OAC discontinuation after catheter ablation conferred
a lower risk of hemorrhagic events (2.4% in rate control strategy and OAC, 1.8% in catheter ablation
with OAC, and no events in catheter ablation and OAC discontinuation, p value < 0.001).
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Based on the aforementioned studies, preservation of sinus rhythm, achieved by AAD therapy or
catheter ablation, holds the potential to confer an improved clinical outcome in the general population.
Among patients with fewer risk factors and lower event rates than those with heart failure, a longer
follow-up and greater sample sizes are possibly needed to identify a statistically significant benefit in
hard clinical end-points. Indeed, maintenance of sinus rhythm can prevent atrial structural remodeling
process accompanying the arrhythmia, hampering disease progression. In this perspective, the
currently ongoing EAST [80] trial will assess if rhythm control therapy in the early phase following AF
diagnosis can improve prognosis in comparison with a more conservative approach; the trial primary
endpoint is a composite of cardiovascular death, stroke, worsening heart failure and myocardial
infarction; cognitive function will be evaluated as a secondary outcome as in the STROKESTOP,
NOAH-AFNET 6, and OCEAN studies. Additionally, two ongoing trials will shed light on another
quandary in clinical management of AF patients: the open, multicenter, randomized OCEAN trial [81]
will compare rivaroxaban and acetylsalicylic acid efficacy in reducing stroke, systemic embolism and
subclinical brain lesions incidence among high-risk patients free from AF for at least 1 year after
pulmonary veins isolation after a 3 years follow-up period. In the OAT trial (NCT01959425) patients
without AF recurrences three months after catheter ablation will be randomized to suspend or continue
OAC. Should these trials meet their outcomes, a rhythm control strategy with catheter ablation in
an early phase of the disease would be recommended aiming to interrupt disease progression and
prevent AF-related complications. Moreover, it would be possible to consider catheter ablation in
asymptomatic patients as well; as a matter of fact, as thoroughly explained by Kalman et al. [82],
subclinical AF can become symptomatic with arrhythmia progression, therefore it may prove useful to
treat the arrhythmia in this early “window of opportunity” in order to prevent symptoms onset and
atrial remodeling. Finally, patients’ compliance to OAC therapy for AF diagnosed after a single ECG
in the absence of any symptoms is of great concern in clinical practice; in this scenario catheter ablation
may be a valid tool potentially providing the expected benefits (Figure 1).
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7. Conclusions
The treatment of asymptomatic AF patients should be personalized, evaluating individual risk
factors and comorbidities as well as patient’s own preference. High risk individuals with heart
failure, should be promptly treated, and catheter ablation should be offered due to the strong evidence
supporting AF ablation in this setting. As for patients with early-diagnosed asymptomatic AF and no
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comorbidities, ongoing clinical trials will assess the benefits of catheter ablation and pharmacological
rhythm control therapy, but currently there is not enough evidence to clearly support this approach.
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